PRO-GLYBURIDE TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
06-06-2013
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
GLYBURIDE
Inapatikana kutoka:
PRO DOC LIMITEE
ATC kanuni:
A10BB01
INN (Jina la Kimataifa):
GLIBENCLAMIDE
Kipimo:
5MG
Dawa fomu:
TABLET
Tungo:
GLYBURIDE 5MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
30/100/500
Dawa ya aina:
Prescription
Eneo la matibabu:
SULFONYLUREAS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0108708001; AHFS:
Idhini hali ya:
CANCELLED POST MARKET
Idhini ya tarehe:
2017-07-04
Tabia za bidhaa
_ _
_PRO-GLYBURIDE _ Product Monograph_ _
_Page 1 of 31_
PRODUCT MONOGRAPH
PR
PRO-GLYBURIDE
Glyburide
Tablets, 5 mg
Manufacturer’s Standard
Oral Hypoglycaemic Agent
ATC Code: A10BB01
PRO DOC LTÉE
2925, boul. Industriel
Laval, Québec
H7L 3W9
DATE OF REVISION:
June 6, 2013
Submission Control No.: 164951
_ _
_PRO-GLYBURIDE _ Product Monograph_ _
_Page 2 of 31_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
CLINICAL TRIALS
..........................................................................................................23
DETAILED PHARM
Soma hati kamili
